Outcome analysis in patients with metastatic gastroenteropancreatic neuroendocrine tumors receiving peptide receptor radionuclide therapy with Lu-177-DOTATATE

BACKGROUND: Patients with neuroendocrine tumors (NET) of the gastroenteropancreatic tract (GEP-NET) were effectively treated with peptide receptor radionuclide therapy (PRRT) with Lu-177-DOTATATE in the NETTER-1 trial. The aim of this study was to assess the outcome of metastatic GEP-NET patients wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Prétot, Dominique, Engel-Bicik, Ivette, Kenkel, David, Kaufmann, Philipp A., Treyer, Valerie, Siebenhüner, Alexander R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10331769/
https://www.ncbi.nlm.nih.gov/pubmed/37435198
http://dx.doi.org/10.21037/jgo-22-874

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10331769/
https://www.ncbi.nlm.nih.gov/pubmed/37435198
http://dx.doi.org/10.21037/jgo-22-874

Ejemplares similares